

Press Release

November 9, 2010

For further information:

Peter Friedli
Neuhofstrasse 8
8834 Schindellegi
Tel: 044/283 29 00
Email: peter.friedli@friedlicorp.ch

New Venturetec: Results for the fiscal year 2010/11 per September 30, 2011

Zug, November 9, 2011. New Venturetec closed the fiscal year 2010/11, ended September 30, 2011, with a loss of USD 6'888'425, compared with a loss of USD 1'523'373 in the fiscal year 2009/10 as announced on October 3, 2011. The main reason for the loss was the decrease of the quoted share price of Osiris Therapeutics by 29.7% from USD 7.28 to USD 5.12. The net asset value per share decreased from USD 6.83 to USD 5.71 which equals -16.4% during the reporting period; in CHF respectively from 6.71 to 5.18 or -22.8%.

As of September 30, 2011, New Venturetec held four investments with two investments valued higher than the investment costs and two below investment costs. The net asset value per September 30, 2011 is USD 28'549'182.

Peter Friedli waived USD 5'097'589 accrued management fee in the reporting period in the form of Inflabloc and Invenda shares in the amount of USD 3'800'430 and the write off of USD 1'297'159. The Infabloc shares which were valued at USD 1'500'000 were subsequently written off and destroyed. Invenda launched a repurchase program at USD 1.00 per share which was based on third party valuation, which was lower than 40 cents per share. Peter Friedli was excluded from participating in this repurchase program. New Venturetec saves interest of approximately USD 200'000 per annum through that transaction. The net impact on the net asset value was an increase of approximately USD 0.26 per share. The management fees for the fiscal year 2010/11 are USD 258'294 of which USD 200'911 has been paid and USD 57'383 was accrued. The board remuneration for each outside board member for the reporting period was reduced from CHF 50'000 to CHF 40'000.

The annual report, including financial statements for the reporting period can be downloaded from www.newventuretec.com/pdf-reports/AnnualReport2011.pdf.

New Venturetec is a publicly traded Swiss investment company (SIX: NEV) which invests directly in venture capital companies in the USA.